TY - JOUR
T1 - Secondary cancer after a childhood cancer diagnosis
T2 - viewpoints considering primary cancer
AU - Ishida, Yasushi
AU - Maeda, Miho
AU - Adachi, Souichi
AU - Inada, Hiroko
AU - Kawaguchi, Hiroshi
AU - Hori, Hiroki
AU - Ogawa, Atsushi
AU - Kudo, Kazuko
AU - Kiyotani, Chikako
AU - Shichino, Hiroyuki
AU - Rikiishi, Takeshi
AU - Kobayashi, Ryoji
AU - Sato, Maho
AU - Okamura, Jun
AU - Goto, Hiroaki
AU - Manabe, Atsushi
AU - Yoshinaga, Shinji
AU - Qiu, Dongmei
AU - Fujimoto, Junichiro
AU - Kuroda, Tatsuo
N1 - Publisher Copyright:
© 2018, Japan Society of Clinical Oncology.
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Backgrounds: Multidisciplinary therapy has increased the risk of subsequent late effects, but detailed analyses on secondary cancers in childhood cancer survivors (CCSs) are limited in Asian countries. Methods: This was a retrospective cohort study comprising 10,069 CCSs who were diagnosed between 1980 and 2009 across 15 Japanese hospitals. We conducted secondary analyses to estimate the incidence of secondary cancer according to each primary malignancy and to elucidate the association between primary and secondary cancers. We also explored the risk factors for the development of secondary cancer in each independent primary malignancy. Results: The cumulative incidence of secondary cancer at 20 years varied among primary cancers: hematological malignancy, 3.1% (95% CI 2.2–4.3); retinoblastoma, 6.6% (95% CI 1.5–16.8); pediatric solid tumor, 2.5% (95% CI 1.3–4.2); brain tumors, 5.2% (95% CI 1.7–11.8) bone/soft tissue sarcoma, 5.2% (95% CI 2.3–10.1); and others, 3.3% (95% CI 1.6–6.0) (p = 0.015). The cumulative incidence of secondary cancers is highest in those with osteosarcoma (13.1%) followed by those with hepatoblastoma (8.4%) and retinoblastoma (6.6%). Close association between the primary and secondary cancer diagnoses was found. The risk factors for secondary cancer development depended on the primary cancer, but autologous/allogeneic stem cell transplantation was a relatively common risk factor. Conclusion: The cumulative incidence of secondary cancer varied among primary cancers. The primary cancer was closely associated with the secondary cancer but stem cell transplantation was a common risk factor for secondary cancers among CCSs.
AB - Backgrounds: Multidisciplinary therapy has increased the risk of subsequent late effects, but detailed analyses on secondary cancers in childhood cancer survivors (CCSs) are limited in Asian countries. Methods: This was a retrospective cohort study comprising 10,069 CCSs who were diagnosed between 1980 and 2009 across 15 Japanese hospitals. We conducted secondary analyses to estimate the incidence of secondary cancer according to each primary malignancy and to elucidate the association between primary and secondary cancers. We also explored the risk factors for the development of secondary cancer in each independent primary malignancy. Results: The cumulative incidence of secondary cancer at 20 years varied among primary cancers: hematological malignancy, 3.1% (95% CI 2.2–4.3); retinoblastoma, 6.6% (95% CI 1.5–16.8); pediatric solid tumor, 2.5% (95% CI 1.3–4.2); brain tumors, 5.2% (95% CI 1.7–11.8) bone/soft tissue sarcoma, 5.2% (95% CI 2.3–10.1); and others, 3.3% (95% CI 1.6–6.0) (p = 0.015). The cumulative incidence of secondary cancers is highest in those with osteosarcoma (13.1%) followed by those with hepatoblastoma (8.4%) and retinoblastoma (6.6%). Close association between the primary and secondary cancer diagnoses was found. The risk factors for secondary cancer development depended on the primary cancer, but autologous/allogeneic stem cell transplantation was a relatively common risk factor. Conclusion: The cumulative incidence of secondary cancer varied among primary cancers. The primary cancer was closely associated with the secondary cancer but stem cell transplantation was a common risk factor for secondary cancers among CCSs.
UR - http://www.scopus.com/inward/record.url?scp=85048035000&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048035000&partnerID=8YFLogxK
U2 - 10.1007/s10147-018-1303-6
DO - 10.1007/s10147-018-1303-6
M3 - Article
C2 - 29869758
AN - SCOPUS:85048035000
SN - 1341-9625
VL - 23
SP - 1178
EP - 1188
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
IS - 6
ER -